Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Astrana Health Narrows FY2025 Sales Guidance from $3.100B-$3.300B to $3.100B-$3.180B vs $3.209B Est

Author: Benzinga Newsdesk | November 06, 2025 04:13pm

2025 Guidance:

Astrana is providing the following updated guidance for total revenue and Adjusted EBITDA for the year ending December 31, 2025 based on the Company's existing business, current view of existing market conditions, and assumptions.

($ in millions)

 		Year Ending

December 31, 2025


 

 		Guidance Range


 

 		Low

 

 		High
Total revenue

 		$3,100

 

 		$3,180
Adjusted EBITDA

 		$200

 

 		$210

Posted In: ASTH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist